Targeting advanced glycation with pharmaceutical agents: where are we now?

Borg, Danielle J. and Forbes, Josephine M. (2016) Targeting advanced glycation with pharmaceutical agents: where are we now?. Glycoconjugate Journal, 33 4: 653-670. doi:10.1007/s10719-016-9691-1

Author Borg, Danielle J.
Forbes, Josephine M.
Title Targeting advanced glycation with pharmaceutical agents: where are we now?
Journal name Glycoconjugate Journal   Check publisher's open access policy
ISSN 1573-4986
Publication date 2016-08-01
Year available 2016
Sub-type Article (original research)
DOI 10.1007/s10719-016-9691-1
Open Access Status Not yet assessed
Volume 33
Issue 4
Start page 653
End page 670
Total pages 18
Place of publication New York, NY United States
Publisher Springer New York
Language eng
Subject 1303 Biochemistry
1312 Molecular Biology
1307 Cell Biology
Abstract Advanced glycation end products (AGEs) are the final products of the Maillard reaction, a complex process that has been studied by food chemists for a century. Over the past 30 years, the biological significance of advanced glycation has also been discovered. There is mounting evidence that advanced glycation plays a homeostatic role within the body and that food-related Maillard products, intermediates such as reactive α-dicarbonyl compounds and AGEs, may influence this process. It remains to be understood, at what point AGEs and their intermediates become pathogenic and contribute to the pathogenesis of chronic diseases that inflict current society. Diabetes and its complications have been a major focus of AGE biology due to the abundance of excess sugar and α-dicarbonyls in this family of diseases. While further temporal information is required, a number of pharmacological agents that inhibit components of the advanced glycation pathway have already showed promising results in preclinical models. These therapies appear to have a wide range of mechanistic actions to reduce AGE load. Some of these agents including Alagebrium, have translated successfully to clinical trials, while others such as aminoguanidine, have had undesirable side-effect profiles. This review will discuss different pharmacological agents that have been used to reduce AGE burden in preclinical models of disease with a focus on diabetes and its complications, compare outcomes of those therapies that have reached clinical trials, and provide further rationale for the use of inhibitors of the glycation pathway in chronic diseases.
Keyword Maillard reaction
Advanced glycation pathway
Advanced glycation end products
Diabetes complications
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 18 Sep 2016, 10:20:39 EST by System User on behalf of Mater Clinical School